Hepatocellular carcinoma (HCC) is among the leading causes of cancer-related mortality.
The principal treatment is surgical resection or liver transplantation, depending on whether …

Portal vein tumour thrombosis is common among patients with advanced hepatocellular
carcinoma. Tremendous differences exist in the management of hepatocellular carcinoma …

Purpose SIRFLOX was a randomized, multicenter trial designed to assess the efficacy and
safety of adding selective internal radiation therapy (SIRT) using yttrium-90 resin …

A multicenter analysis was conducted to evaluate the main prognostic factors driving
survival after radioembolization using yttrium‐90–labeled resin microspheres in patients …

Radioembolization has been demonstrated to allow locoregional therapy of patients with
hepatocellular carcinoma not eligible for transarterial chemoembolization or other local …

Purpose Liver dissemination is a major cause of mortality among patients with advanced
colorectal cancer. Hepatic intra-arterial injection of the β-emitting isotope yttrium-90 (90Y) …

Portal vein tumor thrombosis (PVTT) is a common phenomenon in hepatocellular carcinoma
(HCC). Compared to HCC without PVTT, HCC with PVTT is characterized by an aggressive …

Purpose: The use of 90 Y-microspheres to treat unresectable liver metastases originating
from a variety of neuroendocrine tumors was reviewed. Materials and Methods: This is a …

In hepatic 90Y radioembolization, pretreatment 99mTc-macroaggregated albumin (99mTc-
MAA) nuclear imaging is used for lung shunt analysis, evaluation of extrahepatic deposition …

Since its first suggestion as possible option for liver radioembolization treatment, the
therapeutic isotope holmium-166 (166Ho) caught the experts' attention due to its imaging …